Antipsychotic medication: Effects on regulation of glucose and lipids

Expert Opinion on Pharmacotherapy

Volumn 2, Issue 10, 2001, Pages 1571-1582

  Kato, M M ^a   Goodnick, P J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Antipsychotics; Chlorpromazine; Cholesterol; Clozapine; Diabetes mellitus; Olanzapine; Quetiapine; Risperidone; Triglycerides; Ziprasidone

Indexed keywords

BUTYROPHENONE DERIVATIVE; CHLORPROMAZINE; CHOLESTEROL; CLOPENTHIXOL; CLOZAPINE; FLUPHENAZINE; GLUCOSE; HALOPERIDOL; INSULIN; LIPID; LOXAPINE; MOLINDONE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; PHENOTHIAZINE DERIVATIVE; PROMAZINE; QUETIAPINE; RISPERIDONE; THIORIDAZINE; TIOTIXENE; TRIACYLGLYCEROL; TRIFLUOPERAZINE; ZIPRASIDONE;

AKATHISIA; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; EXTRAPYRAMIDAL SYNDROME; GLUCOSE UTILIZATION; HUMAN; HYPERCHOLESTEROLEMIA; LIPID BLOOD LEVEL; MOTOR DYSFUNCTION; NONHUMAN; REVIEW; SCHIZOPHRENIA; TARDIVE DYSKINESIA; TRIACYLGLYCEROL BLOOD LEVEL; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; GLUCOSE; HUMANS; LIPID METABOLISM; WEIGHT GAIN;

EID: 0034752429     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2.10.1571     Document Type: Review

References (92)

1. Clozapine, diabetes mellitus, weight gain and lipid abnormalities: A five year naturalistic study
2. Prevalence of diabetes and impaired glucose tolerance in patients treated with clozapine compared with patients treated with conventional depot neuroleptic medications
3. Diabetes Mellitus in schizophrenic patients
4. Prevalence and correlates of diabetes in national schizophrenia sample
5. Diabetes trends in the US: 1990-1998
6. The blood sugar curve in mental disease. The schizophrenic (dementia praecox) groups
7. Glucose tolerance in chronic schizophrenia and senile state
8. A hyperglycemia factor in the urine of so-called schizophrenics
9. Blood sugar levels in patients treated with chlorpromazine
10. Psychotropic drugs, diabetes and chronic mental patients
11. Diabetes 1996 vital statistics
12. Hyperglycemia and glycosuria following chlorpromazine therapy
13. The effect of chlorpromazine (Largactil) on glucose tolerance
14. Prorietes pharmacodynamiques du chlorhydrate de chloro-3 (dimethyl-3'propyl) 10 phenothiazine
15. Clozapine and associated diabetes mellitus
16. Novel antipsychotics and new onset diabetes
17. Antipsychotic-induced weight gain: A comprehensive research synthesis
18. Novel antipsychotics: Comparison of weight gain liabilities
19. Weight gain: Side effect of atypical neuroleptics?
20. Weight gain associated with antipsychotic drugs
21. Drug-produced obesity: Experiences with chlorpromazine, perphenazine and clopenthixol
22. Medical hazards of obesity
23. Ziprasidone: A novel antipsychotic with unique pharmacology therapeutic potential
24. Different influences of classical antipsychotics and clozapine on glucose-insulin homeostasis in patients with schizophrenia or related psychosis
25. Peripheral glucose metabolism in human hyperprolactinemia
26. Risperidone and associated amenorrhea: A report of 5 cases
27. Serum triglyceride levels in patients treated with clozapine
28. Mortality and causes of death in schizophrenic patients in Denmark
29. Weight changes during treatment with phenothiazine derivatives
30. Weight changes with schizophrenic psychosis and psychotropic drug therapy
31. The effect of antipsychotic drugs on body weight: A retrospective review
32. Thioridazine improves affective symptoms in schizophrenic patients
33. Antipsychotic-associated weight gain and clinical outcome parameters
34. Weight gain induced by clozapine
35. Differential effect of clozapine on weight: A controlled study
36. Risperidone versus clozapine in treatment-resistant chronic schizophrenia: A randomized double-blind study
37. Olanzapine versus placebo and haloperidol: Acute phase results of the North American double-blind olanzapine trial
38. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial
39. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders
40. Weight gain with atypical antipsychotic medications
41. Ziprasidone versus olanzapine in schizophrenia: Result of a double-blind study
42. Risperidone vs. haloperidol for prevention of relapse in schizophrenia and schizoaffective disorders: A long-term double-blind comparison
43. A comparison of quetiapine and chlorpromazine in the treatment of schizophrenia
44. Multiple fixed doses of ASeroquel(quetiapine) in patients with acute exacerbation of schizophrenia: A comparison with haloperidol and placebo
45. A 28 week comparison of ziprasidone and haloperidol in out-patients with stable schizophrenia
46. Phenothiazines derivatives and glucose metabolism
47. Chlorpromazine induced diabetes
48. Phenothiazines and diabetes in hospitalized women
49. Glucose tolerance in man during chlorpromazine therapy
50. Effects of chlorpromazine on blood glucose and plasma insulin in man
51. Nonketotic hyperglycemia associated with loxapine and amoxapine: Case report
52. Severe hyperglycemia associated high doses of clozapine
53. Diabetic ketoacidosis associated with clozapine treatment
54. Ketoacidosis as a side effect of clozapine: A case report
55. Diabetic ketoacidosis from clozapine and lithium cotreatment
56. Diabetic ketoacidosis and clozapine
57. Hepatitis, hyperglycemia, pleural effusion, eosinophilia, hematuria and proteinuria occurring early in clozapine treatment
58. The effect of clozapine on glucose metabolism
59. Diabetic ketoacidosis associated with clozapine treatment
60. Schizophrenia and diabetes mellitus
61. Diabetic ketoacidosis with clozapine treatment
62. Atypical antipsychotic-associated changes in glucose regulation in schizophrenia may occur independent of changes in adiposity
63. Atypical antipsychotic agents and glucose metabolism: Bergman's MINMOD analysis
64. Hyperglycemia associated with olanzapine
65. Hyperglycemia and olanzapine
66. Diabetic ketoacidosis with olanzapine treatment
67. Olanzapine-induced ketoacidosis with diabetes mellitus
68. New-onset diabetes mellitus and diabetic ketoacidosis associated with olanzapine treatment
69. Olanzapine-induced glucose dysregulation
70. A retrospective comparison of lipid, glucose and weigth changes at one year between olanzapine-and risperidone-treated patients
71. New-onset diabetes and ketoacidosis with atypical antipsychotics
72. Insulin resistance in olanzapine and ziprasidone treated patients: Interim results of a double-blind controlled 6 week trial
73. Risperidone and glucose intolerance
74. Risperidone treatment for a patient suffering from schizophrenia and IDDM
75. Diabetic ketoacidosis associated with risperidone treatment?
76. Risperidone-associated new-onset diabetes
77. New-onset diabetes mellitus associated with the initiation of quetiapine treatment
78. Effects of clozapine-quetiapine combination therapy on weight and glycaemic control
79. Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizo-affective disorder; a four week placebo-controlled trial
80. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizo-affective disorder; a six week placebo-controlled trial
81. The effects of ziprasidone on cholesterol, triglycerides and glucose
82. Effect of prolonged trifluoperazine, imipramine and haloperidol administration on serum cholesterol
83. Chlorpromazine-induced vanishing bile duct syndrome leading to biliary cirrhosis
84. The effect of chlorpromazine on serum cholesterol in chronic schizophrenic patients
85. Serum lipids and lipoproteins in schizophrenic patients receiving major tranquilizers
86. The impact of clozapine on serum lipids in chronic schizophrenic patients
87. Clozapine-associated elevation in serum triglycerides
88. Elevated serum triglycerides on clozapine resolve with risperidone
89. Olanzapine-induced elevation of plasma triglycerides
90. Olanzapine increase weight and serum triglyceride levels